195 related articles for article (PubMed ID: 12871024)
1. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
Marriott JB; Dredge K; Dalgleish AG
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
[TBL] [Abstract][Full Text] [Related]
2. Immunological effects of thalidomide and its chemical and functional analogs.
Dredge K; Marriott JB; Dalgleish AG
Crit Rev Immunol; 2002; 22(5-6):425-37. PubMed ID: 12803319
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide analogs as emerging anti-cancer drugs.
Dredge K; Dalgleish AG; Marriott JB
Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide: a novel template for anticancer drugs.
Stirling D
Semin Oncol; 2001 Dec; 28(6):602-6. PubMed ID: 11740817
[TBL] [Abstract][Full Text] [Related]
5. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
6. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.
Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG
Br J Cancer; 2002 Nov; 87(10):1166-72. PubMed ID: 12402158
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic and antitumour potential of thalidomide analogues.
Marriott JB; Muller G; Stirling D; Dalgleish AG
Expert Opin Biol Ther; 2001 Jul; 1(4):675-82. PubMed ID: 11727503
[TBL] [Abstract][Full Text] [Related]
9. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of thalidomide and its analogues.
De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Bodera P; Stankiewicz W
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
[TBL] [Abstract][Full Text] [Related]
12. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide treatment in multiple myeloma.
Strasser K; Ludwig H
Blood Rev; 2002 Dec; 16(4):207-15. PubMed ID: 12350364
[TBL] [Abstract][Full Text] [Related]
14. The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Bartlett JB; Dredge K; Dalgleish AG
Nat Rev Cancer; 2004 Apr; 4(4):314-22. PubMed ID: 15057291
[No Abstract] [Full Text] [Related]
15. A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders.
Millrine D; Kishimoto T
Trends Mol Med; 2017 Apr; 23(4):348-361. PubMed ID: 28285807
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide and its derivatives: emerging from the wilderness.
Gordon JN; Goggin PM
Postgrad Med J; 2003 Mar; 79(929):127-32. PubMed ID: 12697909
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide: an old drug with new clinical applications.
Laffitte E; Revuz J
Expert Opin Drug Saf; 2004 Jan; 3(1):47-56. PubMed ID: 14680461
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide - current understanding of mechanistic properties.
Tageja N
Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide and immunomodulatory drugs as cancer therapy.
Raje N; Anderson KC
Curr Opin Oncol; 2002 Nov; 14(6):635-40. PubMed ID: 12409654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
